News about Global Pharma

Antengene Announces XPOVIO Approved for Public Health Insurance Coverage in Taiwan Market

With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in nine countries and regions in APAC, and included in the public insurance schemes in five of those markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea).

Global Pharma | 13/02/2025 | By Manvi |  752

Burkert Fluid Control Systems Acquires Stake in Green Elephant Biotech

The partnership gives Bürkert access to the latest trends and developments in the biopharmaceutical industry, one of the strategic core markets of the fluidics specialist from Ingelfingen.

Global Pharma | 13/02/2025 | By Aishwarya |  700

Royalty Pharma Signs R&D Funding Agreement with Biogen

Litifilimab is currently in Phase 3 trials for both SLE and CLE with results expected between 2026 and 2027.

Global Pharma | 13/02/2025 | By Aishwarya |  291

Zydus and Synthon to Commercialise Novel 505(B)(2) Oncology Product in US

Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product.

Global Pharma | 13/02/2025 | By Aishwarya |  607

Oramed to Accelerate Development and Commercialization of Oral Insulin

As part of the transaction, Oramed will transfer its proprietary oral insulin and POD™ technology, along with other pipeline assets, into OraTech.

Global Pharma | 13/02/2025 | By Aishwarya |  408

Lion TCR Receives FDA Clearance to Launch Phase 2 International Trial for mRNA-Encoded TCR-T Cell Therapy Liocyx-M004

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial.

Global Pharma | 12/02/2025 | By Manvi |  435

Alloy Therapeutics and Pfizer to Develop New Antibody Discovery Platform

Pfizer and Alloy have collaborated on various antibody discovery efforts, including the use of Alloy's ATX-CLC platform.

Global Pharma | 12/02/2025 | By Aishwarya |  260

Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront

Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.

Global Pharma | 12/02/2025 | By Aishwarya |  474

Everest Group Recognises Indegene as Front-Runner in GenAI Life Sciences Market Adoption

The report highlights how Indegene’s holistic GenAI strategy and enterprise-grade, production-ready solutions are helping life sciences companies streamline operations and realize strong productivity improvements across several use cases, spanning the clinical, medical and commercial elements of the life sciences value chain.

Global Pharma | 12/02/2025 | By Aishwarya |  283

Synexa Life Sciences Achieves 'My Green Lab Certification'

Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries, has achieved the My Green Lab Certification at the highest ‘Green’ level at its Cape Town, South Africa facility.

Global Pharma | 11/02/2025 | By Manvi |  435